Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Pepgen Logo
Pepgen Growth Score
69
CB Rank
15016
Heat Score
54
PepGen is empowering nucleic acid therapeutics to go the distance.
Founded
obfuscation
PublicPost-IPO Equity Oxford, Oxfordshire, United Kingdom51-100 pepgen.com/
Biotechnology
Clinical Trials
Medical
Overview

Pepgen
Total Funding
obfuscation
Growth Score
69
Heat Score
54

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score69
-16 pts
in past quarter
Heat Score 54
-16 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Pepgen

CB Rank
15016
PepGen is empowering nucleic acid therapeutics to go the distance.
Founded
obfuscation
PublicPost-IPO Equity Oxford, Oxfordshire, United Kingdom51-100 pepgen.com/
Biotechnology
Clinical Trials
Medical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Venture - Series Unknown
OBF
in
obfuscation

Key People

  • Photo of Paul Streck
    Paul Streck: EVP, Head of Research and Development
    Past Role: Albireo Pharma, Chief Medical Officer
  • Photo of Jaya Goyal
    Jaya Goyal: Executive Vice President, Research & Preclinical Development

Details

Legal Name PepGen Inc
Operating Status Active
Stock Symbol  NASDAQ:PEPG
Company Type For Profit
Founders  Caroline Godfrey, Matthew Wood, Michael Gait
About the Company

PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,

and they are advancing novel conjugate therapeutics to the clinic.

Phone Number +44 1865 618 820
Contact Email info@pepgen.com
Predictions & Insights

Growth Insight

See this Growth Insight
Pepgen is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Enhanced Delivery Oligonucleotide (EDO) Platform
A technology platform that conjugates peptides to oligonucleotides to improve delivery and uptake in muscle tissues for treating neuromuscular diseases.
PGN-EDODM1
An investigational peptide-conjugated oligonucleotide therapy candidate for treating myotonic dystrophy type 1 (DM1) using the EDO platform.

Research & Development

Pepgen is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Janus Henderson Investors Logo
Janus Henderson Investors
—
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
Janus Henderson Investors Logo
Janus Henderson Investors
—
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
Janus Henderson Investors Logo
Janus Henderson Investors
—
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
Janus Henderson Investors Logo
Janus Henderson Investors
—
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
Janus Henderson Investors Logo
Janus Henderson Investors
—
Post-IPO Equity - Pepgen Logo
Post-IPO Equity - Pepgen
—
Market Intelligence
People
View Profiles & Contacts
Headcount 51-100 Employee Profiles 8 Board Members and Advisors 1 Contacts 60

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 21, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 21, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 19, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 13, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

2,165
-14.19%
 in past month

Interest Signals

TopicSurge Score
Panasonic (PCRFY) Logo
Panasonic (PCRFY)
96
Conflict Resolution Logo
Conflict Resolution
95
Company Relocation Logo
Company Relocation
91

Active Website Tech Count

16Pepgen is actively using 16 technologies for its website, according to BuiltWith. These include CommonCrawl Top 5m, jQuery CDN, and  COVID-19.
Sub-Organizations
Frequently Asked Questions

Where is Pepgen's headquarters? Pepgen is located in Oxford, Oxfordshire, United Kingdom.Who invested in Pepgen? Pepgen has 20 investors including Janus Henderson Investors and  Monashee Investment Management.When was the last funding round for Pepgen? Pepgen closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Pepgen's competitors? Alternatives and possible competitors to Pepgen may include LEXEO Therapeutics, Hatteras Venture Partners, and  Juvena Therapeutics.How much funding has Pepgen raised to date? Pepgen has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(05b78c5 1)
|